AU2018341235A1 - Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation - Google Patents

Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation Download PDF

Info

Publication number
AU2018341235A1
AU2018341235A1 AU2018341235A AU2018341235A AU2018341235A1 AU 2018341235 A1 AU2018341235 A1 AU 2018341235A1 AU 2018341235 A AU2018341235 A AU 2018341235A AU 2018341235 A AU2018341235 A AU 2018341235A AU 2018341235 A1 AU2018341235 A1 AU 2018341235A1
Authority
AU
Australia
Prior art keywords
cyclodextrin
disease
subject
derivative
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018341235A
Other languages
English (en)
Inventor
Knut M. Wittkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asdera LLC
Original Assignee
Asdera LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asdera LLC filed Critical Asdera LLC
Publication of AU2018341235A1 publication Critical patent/AU2018341235A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
AU2018341235A 2017-09-28 2018-09-18 Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation Abandoned AU2018341235A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762565053P 2017-09-28 2017-09-28
US62/565,053 2017-09-28
US201762573658P 2017-10-17 2017-10-17
US62/573,658 2017-10-17
US201762586826P 2017-11-15 2017-11-15
US62/586,826 2017-11-15
US201862643694P 2018-03-15 2018-03-15
US62/643,694 2018-03-15
US201862679912P 2018-06-03 2018-06-03
US62/679,912 2018-06-03
PCT/US2018/051604 WO2019067269A2 (en) 2017-09-28 2018-09-18 USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION

Publications (1)

Publication Number Publication Date
AU2018341235A1 true AU2018341235A1 (en) 2020-05-07

Family

ID=65903379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018341235A Abandoned AU2018341235A1 (en) 2017-09-28 2018-09-18 Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

Country Status (7)

Country Link
US (1) US11471478B2 (https=)
EP (1) EP3687549A4 (https=)
JP (1) JP2020535235A (https=)
KR (1) KR20200107927A (https=)
AU (1) AU2018341235A1 (https=)
CA (1) CA3076821A1 (https=)
WO (1) WO2019067269A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
LU100797B1 (en) * 2018-05-15 2019-11-15 Univ Luxembourg 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
BE1027425B1 (fr) 2019-07-01 2021-02-08 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales
US11446325B2 (en) 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
US12285440B2 (en) * 2021-03-14 2025-04-29 Massachusetts Institute Of Technology APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia
CN115245567B (zh) * 2021-12-11 2023-06-06 中国药科大学 Fgl1抑制剂在制备防治心肌缺血损伤的药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
PL220776B1 (pl) 2002-08-19 2016-01-29 Soho Flordis Internat Pty Ltd Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki
WO2005011710A1 (en) 2003-07-28 2005-02-10 The Board Of Trustees Of The University Of Illinois Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US9034846B2 (en) 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
ATE542527T1 (de) * 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
US7664616B2 (en) 2006-02-16 2010-02-16 Rockefeller University Statistical methods for hierarchical multivariate ordinal data which are used for data base driven decision support
WO2008067027A2 (en) 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2114374A4 (en) * 2006-12-27 2011-03-23 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
CN101704761B (zh) 2009-10-23 2012-09-05 宁波斯迈克制药有限公司 甲灭酸的合成方法
CN103841961A (zh) 2011-07-28 2014-06-04 雪松-西奈医学中心 在两亲性间隔基或两亲性聚合物上包含治疗剂的抗氧化剂、神经保护和抗肿瘤纳米颗粒
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
JP5703426B2 (ja) * 2012-12-07 2015-04-22 国立大学法人 熊本大学 ヒドロキシアルキル化シクロデキストリンを含む腫瘍細胞選択的抗がん剤
JP6010001B2 (ja) 2013-06-28 2016-10-19 京セラドキュメントソリューションズ株式会社 画像形成装置
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
WO2015035258A1 (en) 2013-09-06 2015-03-12 The Rockefeller University Treatment and prevention of autism and autism spectrum disorders
US10597696B2 (en) 2013-09-18 2020-03-24 University Of Notre Dame Du Lac Detection of Niemann-Pick disease comprising detection of lysozyme and cathepsins
WO2015083736A1 (ja) 2013-12-05 2015-06-11 国立大学法人熊本大学 コレステロール蓄積疾患治療薬、およびそのスクリーニング方法
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
TW201617084A (zh) * 2014-09-25 2016-05-16 山口龍二 包含β－環糊精之抗腫瘤劑
GB201417165D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
MX2018006247A (es) 2015-11-19 2018-11-29 Aztherapies Inc Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
US20200000840A1 (en) 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders
WO2019067145A1 (en) 2017-08-28 2019-04-04 Asdera Llc USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도

Also Published As

Publication number Publication date
JP2020535235A (ja) 2020-12-03
CA3076821A1 (en) 2019-04-04
WO2019067269A2 (en) 2019-04-04
US20200276225A1 (en) 2020-09-03
KR20200107927A (ko) 2020-09-16
WO2019067269A3 (en) 2020-03-26
EP3687549A2 (en) 2020-08-05
EP3687549A4 (en) 2021-07-14
US11471478B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
US20230130066A1 (en) Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
US11471478B2 (en) Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
Bonora et al. Physiopathology of the permeability transition pore: molecular mechanisms in human pathology
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
US20250114330A1 (en) (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US9808501B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US20200000840A1 (en) Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders
Demirsoy et al. Adapt, recycle, and move on: Proteostasis and trafficking mechanisms in melanoma
US20160193231A1 (en) Rett syndrome and treatments therefore
KR20210045364A (ko) 악성 림프증식성 장애를 치료하는 방법
US12419847B2 (en) Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy
JP2023516753A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
US10272133B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
Li et al. PROTAC-Mediated Multi-Target Protein Degradation in Alzheimer’s Disease: Mechanistic Insights, Therapeutic Applications, and Translational Challenges
JP7849841B2 (ja) リソソーム関連膜タンパク質標的化化合物及びその使用
EP4445949A1 (en) Medicine for steatohepatitis
US20230201183A1 (en) Methods to synergistically enhance multiple cellular proteostasis pathways to treat neurodegeneration and storage diseases
Risso Effect of CYP46A1 ectopic expression on recovery from liver disease in a Niemann-Pick type C mouse model
McCabe Chemical Modulation of the NCoR1/RARα Axis for Regulation of Chaperone-Mediated Autophagy in Disease
Dobi Lipid-based approaches to optimize the effectiveness of innovative drug modulators in Cystic Fibrosis
Wittkowski et al. Complex polymorphisms in endocytosis genes suggest alpha-cyclodextrin against metastases in breast cancer
WO2024264025A2 (en) Therapeutic targeting of hypdh/prodh2 and prodh1 to suppress 4-hydroxyproline and proline catabolism
WITTKOWSKI et al. Complex polymorphisms in endocytosis genes suggest alpha-cyclodextrin as a treatment for breast cancer Alpha-cyclodextrin as a treatment for breast cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period